Login / Signup

[Thrombosis in patients with myeloproliferative neoplasms. Case report].

A L MelikyanI N SubortsevaE A GilyazitdinovaT I KoloshejnovaK S ShashkinaE K EgorovaA M KovriginaAndrey Borisovich SudarikovLana Gorgidze
Published in: Terapevticheskii arkhiv (2021)
Thrombotic complications are the most significant factors determining the prognosis in myeloproliferative neoplasms. Markers for assessing the risk of thrombosis are the number of leukocytes, platelets, hemoglobin level, hematocrit, age, molecular status, history of thrombosis, obesity, arterial hypertension, hyperlipidemia, hereditary or acquired thrombophilia. The pathogenesis of thrombosis in patients with myeloproliferative neoplasms is complex and multifactorial. In most cases, the etiological factor remains unknown. Currently, antiplatelet and anticoagulant therapy is carried out on an individual basis. The algorithm for primary and secondary (after thrombosis) prevention requires development and testing. We present a clinical case of repeated arterial and venous thrombotic complications in a patient with primary myelofibrosis.
Keyphrases
  • pulmonary embolism
  • case report
  • arterial hypertension
  • risk factors
  • venous thromboembolism
  • atrial fibrillation
  • machine learning
  • stem cells
  • deep learning
  • physical activity
  • body mass index
  • adipose tissue